Vivo Capital LLC Has $7.95 Million Stock Position in Delcath Systems, Inc. (NASDAQ:DCTH)

Vivo Capital LLC boosted its position in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 94.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,666,746 shares of the company's stock after buying an additional 811,555 shares during the quarter. Vivo Capital LLC owned approximately 6.55% of Delcath Systems worth $7,950,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. AIGH Capital Management LLC acquired a new position in shares of Delcath Systems during the fourth quarter worth approximately $4,918,000. Stonepine Capital Management LLC increased its position in Delcath Systems by 81.2% during the third quarter. Stonepine Capital Management LLC now owns 686,240 shares of the company's stock worth $2,779,000 after acquiring an additional 307,453 shares during the period. Worth Venture Partners LLC acquired a new position in Delcath Systems during the 4th quarter valued at $1,224,000. ADAR1 Capital Management LLC bought a new stake in Delcath Systems in the 4th quarter valued at $962,000. Finally, Armistice Capital LLC acquired a new stake in Delcath Systems in the 3rd quarter worth $664,000. Institutional investors own 61.12% of the company's stock.

Insider Transactions at Delcath Systems

In other news, Director Gil Aharon purchased 26,882 shares of the company's stock in a transaction that occurred on Tuesday, March 19th. The stock was acquired at an average cost of $3.72 per share, with a total value of $100,001.04. Following the acquisition, the director now owns 1,069,710 shares in the company, valued at approximately $3,979,321.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 17.94% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently commented on DCTH. HC Wainwright upped their target price on Delcath Systems from $18.00 to $20.00 and gave the company a "buy" rating in a research note on Wednesday, March 27th. StockNews.com raised shares of Delcath Systems to a "sell" rating in a report on Wednesday, March 27th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Delcath Systems presently has a consensus rating of "Moderate Buy" and an average target price of $18.50.

Delcath Systems Stock Performance

NASDAQ DCTH traded up $0.04 during trading hours on Friday, reaching $5.30. 165,118 shares of the company's stock were exchanged, compared to its average volume of 222,580. Delcath Systems, Inc. has a one year low of $2.25 and a one year high of $7.99. The company's 50-day moving average is $4.55 and its two-hundred day moving average is $3.97. The company has a market capitalization of $134.83 million, a price-to-earnings ratio of -1.78 and a beta of 0.53.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last posted its quarterly earnings data on Tuesday, March 26th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.67) by $0.19. The company had revenue of $0.54 million for the quarter, compared to the consensus estimate of $0.48 million. Delcath Systems had a negative net margin of 2,308.86% and a negative return on equity of 563.60%. During the same period last year, the company earned ($0.86) earnings per share. Research analysts predict that Delcath Systems, Inc. will post -1.45 earnings per share for the current fiscal year.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.